Figures
Abstract
The main side effect of cyclosporine A (CsA), a widely used immunosuppressive drug, is nephrotoxicity. Early detection of CsA-induced acute nephrotoxicity is essential for stop or minimize kidney injury, and timely detection of chronic nephrotoxicity is critical for halting the drug and preventing irreversible kidney injury. This study aimed to identify urinary biomarkers for the detection of CsA-induced nephrotoxicity. We allocated salt-depleted rats to receive CsA or vehicle for 7, 14 or 21 days and evaluated renal function and hemodynamics, microalbuminuria, renal macrophage infiltration, tubulointerstitial fibrosis and renal tissue and urinary biomarkers for kidney injury. Kidney injury molecule-1 (KIM-1), tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), fibronectin, neutrophil gelatinase-associated lipocalin (NGAL), TGF-β, osteopontin, and podocin were assessed in urine. TNF-α, IL-6, fibronectin, osteopontin, TGF-β, collagen IV, alpha smooth muscle actin (α -SMA) and vimentin were assessed in renal tissue. CsA caused early functional renal dysfunction and microalbuminuria, followed by macrophage infiltration and late tubulointerstitial fibrosis. Urinary TNF-α, KIM-1 and fibronectin increased in the early phase, and urinary TGF-β and osteopontin increased in the late phase of CsA nephrotoxicity. Urinary biomarkers correlated consistently with renal tissue cytokine expression. In conclusion, early increases in urinary KIM-1, TNF-α, and fibronectin and elevated microalbuminuria indicate acute CsA nephrotoxicity. Late increases in urinary osteopontin and TGF-β indicate chronic CsA nephrotoxicity. These urinary kidney injury biomarkers correlated well with the renal tissue expression of injury markers and with the temporal development of CsA nephrotoxicity.
Citation: Carlos CP, Sonehara NM, Oliani SM, Burdmann EA (2014) Predictive Usefulness of Urinary Biomarkers for the Identification of Cyclosporine A-Induced Nephrotoxicity in a Rat Model. PLoS ONE 9(7): e103660. https://doi.org/10.1371/journal.pone.0103660
Editor: Partha Mukhopadhyay, National Institutes of Health, United States of America
Received: March 30, 2014; Accepted: July 3, 2014; Published: July 29, 2014
Copyright: © 2014 Carlos et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.
Funding: This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo, SP, Brazil (FAPESP); grant 09/17100-2 to EAB) and Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil (CNPq), Brazil; grants 150954/2009-3 to CPC and 302768/2010-6 to SMO. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors confirm that co-author Emmanuel A. Burdmann is a PLOS ONE Editorial Board member. This does not alter the authors' adherence to PLOS ONE Editorial policies and criteria.
Introduction
The main side effect of CsA, a widely used immunosuppressant agent, is nephrotoxicity, which can be manifested as acute or chronic. Acute nephrotoxicity is a functional and reversible phenomenon, whereas chronic nephrotoxicity is characterized by irreversible interstitial fibrosis, which usually leads to impaired renal function [1].
The therapeutic window for CsA is narrow and variable, and CsA blood levels are little help in predicting kidney injury development. CsA-induced nephrotoxicity is usually diagnosed only when serum creatinine increases, denoting a significant impairment of the glomerular filtration rate (GFR). The line between a functional reversible injury and irreversible chronic tubulointerstitial fibrosis is inexact. In fact, significant structural injury can occur in the presence of normal or minimally altered serum creatinine levels [2]. The identification of biomarkers that timely detects the initiation of CsA nephrotoxicity and enable its progression to be monitored would be extremely useful, allowing maneuvers to halt or minimize kidney injury progression.
Several urinary biomarkers for the detection of kidney injury have been tested [3]–[4], but few studies have evaluated urinary biomarkers specific for diagnosing CsA-induced nephrotoxicity.
The aim of this study was to investigate urinary biomarkers for the identification of both acute and chronic CsA nephrotoxicity and to correlate them with the development of functional and structural changes in a rat model of CsA-induced nephrotoxicity. Those urinary biomarkers included kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) [5]–[8]; podocin [9]–[10]; osteopontin, tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6) and microalbuminuria [11]–[18]; and TGF-β, alpha-smooth muscle actin (α-SMA), collagen and fibronectin [19]–[21].
Materials and Methods
Study Design
The Ethical Animal Experimentation Committee of São José do Rio Preto Medical School, Brazil, approved the protocol and all the procedures (process 3992/2009).
Groups of eight male Munich-Wistar rats weighing approximately 250 g (São José do Rio Preto Medical School) were randomly assigned to receive CsA (treatment group) or vehicle (control group, VH). CsA powder was dissolved in VH (12.5% ethanol and 87.5% olive oil) to a final concentration of 15 mg/mL. The treatment group received a daily subcutaneous injection of CsA (15 mg/kg/day) for 7, 14 or 21 days. The control group received a daily subcutaneous injection of VH (1 mL/kg body weight) for 7, 14 or 21 days.
The animals received a low-salt diet of cooked rice (0.05% sodium, 8.5% protein, 76.6% carbohydrate, less than 4.3% fat) combined with amino acid supplements (Aminomix Pet; Vetnil Ind. Com. Prod. Veterinários Ltda; Louveira, SP, Brazil), starting one week before treatment and continuing throughout the study. Dietary consumption and weight gain were verified on a daily basis. Control animals were pair-fed with CsA-treated rats. The animals were allowed ad libitum access to water.
After 7, 14 and 21 days of treatment, rats were placed in metabolic cages (Nalgene, NY, USA). Their urine volume was collected and measured for 24 hours, and urine samples were taken at the final of this period.
The animals were then submitted to renal function studies, including GFR and renal blood flow (RBF). At the end of the renal function experiments, blood samples (3 mL) were drawn, the animals were euthanized with intravenously injected thiopental (100 mg/kg body weight), and renal tissue samples were collected.
Renal Function Studies
GFR and RBF assessments were performed 24 h after the last injection of CsA or VH. After anesthesia with intraperitoneal thiopental (50 mg/kg body weight), tracheotomy was performed, and polyethylene tubes (PE-50) were placed in the carotid artery to monitor the mean arterial pressure and in the jugular vein to collect blood and perform infusions. A PE 190 polyethylene tube was inserted in the urinary bladder through a lower median abdominal incision for urine collection. Next, a ventral midline incision was made, exposing the renal artery. A suitable probe (R series, 1.5 mm, with J reflector; Transonic Systems Inc., Ithaca, NY, USA) was placed around the renal artery. A loading injection of 5 mL of 0.9% NaCl was administered, and each animal received a loading dose of 1 mL of inulin (Sigma Chemical Co., St. Louis, MO, USA) diluted in 0.9% NaCl (1 mg/mL), followed by a maintenance infusion of the same solution at 0.06 mL/min. After a 50-min equilibration, urine was collected in previously weighed vials during three 20-min periods. A blood sample (0.3 mL) was drawn at the midpoint of each urine collection and was replaced with an equal volume of 0.9% NaCl. This approach for volume infusion (loading dose, rate of infusion pump and replacements after blood collection) has been shown previously to replace adequately volume losses during experiment. Serum and urine inulin levels were measured using a colorimetric assay (anthrone method, BTS 310 spectrophotometer; BioSystems, Barcelona, Spain). The inulin clearance values, expressed as mL/min/100 g body weight, are presented as the mean of the three clearance periods. The MAP results are presented as the mean of all the recordings during the MAP period. Ultrasonic transit-time RBF measurements were taken (T 106; Transonic Systems Inc., Ithaca, NY, USA) during a 60-min observation period (measured over six points at 10-min intervals). MAP measurements were taken concurrently, and the renal vascular resistance (RVR) was calculated. RBF and RVR are presented as the mean of the six observation periods.
Markers in Urine and Blood Samples
Electrolytes, Creatinine, Osmolality, Microalbuminuria, Cyclosporine, Hematocrit.
Sodium and potassium levels were determined using an electrolyte analyzer (Mod. 9180; AVL Scientific Co., Roswell, GA, USA), and creatinine levels were ascertained with a colorimetric assay (BTS 310 spectrophotometer; BioSystems, Barcelona, Spain) in the 24-hour urine and in the blood samples taken after the renal function studies. Urinary osmolality was determined by freezing point depression (Osmette A; Precision Systems Inc., Natick, MA, USA) in the 24-hour urine. Microalbuminuria was assessed in the 24-hour urine with a colorimetric assay (BTS 310 spectrophotometer; BioSystems, Barcelona, Spain). CsA blood levels were analyzed by double antibody radioimmunoassay (CYCLO-Trac SP; DiaSorin, Stillwater, MN, USA), and hematocrit was assessed by the microhematocrit method in the blood samples taken after the renal function studies.
Urinary Biomarkers for CsA Nephrotoxicity
The biomarkers were quantified by ELISA at the end of each time period (7, 14 and 21 days) using the 24-hour urine.
KIM-1 (RKM 100, R&D Systems, Minneapolis, USA) was used to identify proximal tubular and acute kidney injury. NGAL (KIT 046, BioPorto, Denmark) was used as a tubular and acute kidney injury biomarker. Fibronectin (KT-415, Kamiya, WA, USA) and TGF-β (G7590, Promega, WI, USA) were used as fibrosis biomarkers. Osteopontin (ADI-900-090A, Enzo, PA, USA), TNF-α (CKR041, Cell Sciences, MA, USA) and IL-6 (DY506, R&D Systems, Minneapolis, USA) were used as markers of macrophage infiltration and inflammation, and podocin (E90938Ra, Uscn Life Science Inc., P.R. China) served as a glomerular damage biomarker.
Markers in Tissue Samples
Histopathological Analysis (Glomerular Injury and Tubulointerstitial Fibrosis).
Renal fragments collected at the end of the renal function studies were fixed with 4% paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4) for 24 h at 4°C, placed in 70°C ethanol, and embedded in paraffin. Longitudinal sections 5-µm thick were stained via Gomori's process. The presence of interstitial fibrosis was detected based on the presence of green fibers, and was considered indicative of chronic injury. The tissues were evaluated for glomerular injury and tubulointerstitial fibrosis with a higher power objective (40×) on an Axioskop MOT Plus II Microscope (Carl Zeiss, Jena, Germany) by a blinded observer.
Immunohistochemical Analysis
The immunohistochemical analysis was used to identify tissue markers of early, middle and later CsA-induced injury. Thus, osteopontin, TNF-α, IL-6 and ED-1 (macrophage antigen) were indicative of leukocyte infiltration and inflammation at all-time points studied. Collagen IV, α-SMA, vimentin and TGF-β were indicative of middle to later lesion.
The primary antibodies used for immunohistochemical analysis of the renal tissue collected at the end of the renal function studies were monoclonal anti-ED1 (macrophage antigen; MCA341R, Serotec, Oxford, United Kingdom); polyclonal anti-TGF-β (sc-7892, Santa Cruz, CA, USA); monoclonal anti-fibronectin (MAB1926, Millipore, CA, USA); monoclonal anti-collagen IV (MAB1910, Millipore, CA, USA); polyclonal anti-osteopontin (AB1870, Millipore, CA, USA); monoclonal anti-IL-6 (840234, R&D, Minneapolis, USA); monoclonal anti-TNF-α (840174, R&D Systems, Minneapolis, USA); monoclonal anti-α-SMA (M0851, Dako, Denmark); and monoclonal anti-vimentin antibody (M0725, Dako, Denmark).
Paraffin-embedded sections (3 µm) were incubated for 20 min with sodium citrate at 96°C. Then, kidney fragments were treated with 3% hydrogen peroxide diluted in methanol for 30 min. The sections were subsequently incubated overnight at 4°C with antibodies against α-SMA (1∶1000), TGF-β (1∶80), collagen IV (1∶250), osteopontin (1∶500), TNF-α (1∶100), IL-6 (1∶100) and fibronectin (1∶100) or at room temperature for 1 hour with anti-ED1 (1∶1000) and anti-vimentin (1∶500) antibodies. Nonspecific protein binding was blocked by simultaneous incubation with 1% bovine serum albumin (BSA) in PBS. Negative controls were incubated with an equivalent concentration of 1% PBS-BSA instead of primary antibody. Subsequently, the sections were incubated for 30 min with a biotinylated secondary antibody followed by avidin-conjugated horseradish peroxidase (K0690 kit, Dako, CA, USA) and then enhanced with diaminobenzidine chromogenic substrate (LSAB detection kit, K3468, Dako, CA, USA) at room temperature. The sections were counterstained with hematoxylin, dehydrated, and mounted. Analysis of the renal cortex was performed with a Zeiss Axioskop 2 (Zeiss, Jena, German) using AxioVision software (Carl Zeiss, Jena, Germany). In the immunostaining for α-SMA, the periglomerular areas were assessed separately. To determine the number of infiltrating macrophages (ED1-positive cells) in the renal cortical tubulointerstitial area, 25 grid fields of the renal cortex were analyzed (Zeiss Axioskop 2). An observer blinded to the treatment groups evaluated all the slides at random.
Results
CsA-treated animals had elevated CsA blood levels and reduced significantly their body weight compared with VH-treated animals. The hematocrit was similar in all groups. These results are summarized in Table 1.
Renal Function in the Treatment and Control Groups
CsA significantly reduced the GFR and the RBF and significantly increased renal vascular resistance when compared with VH at all time points analyzed. Creatinine clearance was significantly reduced in the CsA treatment groups after 14 and 21 days of treatment (Table 1). Urinary output did not differ among the groups at any studied time point. CsA-treated animals had significantly lower urinary osmolality after 7, 14 and 21 days of treatment. The fractional excretion of potassium was significantly increased in the CsA group compared with the VH group after 21 days of treatment (Table 1). All studied groups presented extremely low urinary sodium levels and urinary osmolality due to the low-salt diet. These results confirmed the efficacy of the intervention in generating the groups for comparison in the present study.
Early Injury (7 days)
Urinary Biomarkers.
After 7 days the microalbuminuria, urinary KIM-1, TNF-α, and fibronectin were significantly increased in CsA-treated animals when compared with VH-treated rats (Table 1 and Figure 1). When compared to controls, microalbuminuria increased 3.6 times, KIM-1 6.2 times, TNF-α 5.4 times and fibronectin 2.3 times.
Urinary ELISA assays (ng/mL) after 7, 14 or 21 days of treatment with vehicle (VH) or 15 mg/kg cyclosporine (CsA). The data are presented as the mean ± SD. * p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001 (CsA versus VH).
Renal Tissue Histochemistry and Immunohistochemistry.
After one week, the renal expression of osteopontin (Figure 2 and Figure 3B), collagen IV (Figure 2 and Figure 4B) and fibronectin (Figure 2 and Figure 4F) was significantly upregulated in CsA-treated rats compared with the control group.
Mean optical densitometry, MOD, arbitrary units after 7, 14 or 21 days of treatment with vehicle (VH) or 15 mg/kg cyclosporine (CsA). The data are presented as the mean ± SD. * p<0.05, ** p<0.01 and *** p<0.001 (CsA versus VH).
Osteopontin (A–D), TNF-α (E–H) and IL-6 (I–L) after 7, 14 or 21 days of treatment with vehicle (VH) or 15 mg/kg cyclosporine (CsA). Black arrows indicate renal inflammation, p≤0.01 (B–D and H). Hematoxylin counterstain. Bars = 10 µm.
Collagen IV (A–D), fibronectin (E–H) and TGF-β (I–L) after 7, 14 or 21 days of treatment with vehicle (VH) or 15 mg/kg cyclosporine (CsA). Black arrows indicate renal inflammation and injury, p≤0.05 (B–D, F–G and L). Hematoxylin counterstain. Bars = 10 µm.
Mid-Term Injury (14 days)
Urinary Biomarkers.
After two weeks, microalbuminuria in the treatment group decreased to values similar to those in the control group. Urinary KIM-1, TNF-α, and fibronectin remained significantly increased in CsA-treated animals (4.4, 2.1 and 1.3 times, respectively). At this time point, urinary osteopontin increased significantly (1.6 times) in CsA-treated rats (Table 1 and Figure 1).
Renal Tissue Histochemistry and Immunohistochemistry.
The renal expression of osteopontin (Figure 2 and Figure 3C), collagen IV (Figure 2 and Figure 4C) and fibronectin (Figure 2 and Figure 4G) remained significantly upregulated in rats treated with CsA after 14 days. At this time point, tubulointerstitial α-SMA (Figure 2 and Figure 5G) was increased significantly in CsA-treated animals. After two weeks, the number of renal macrophages was significantly higher in CsA-treated rats (Figure 6) than in control rats.
Collagen fibers stained green by Gomori's method (A–D). Red arrows indicate fibrosis (D). Immunolocalization of tubulointerstitial α-SMA (E–H) and vimentin (I–L) after 7, 14 or 21 days of treatment with vehicle (VH) or 15 mg/kg cyclosporine (CsA). Black arrows indicate renal injury, p≤0.001 (G–H and L). Hematoxylin counterstain. Bars = 10 µm.
Immunohistochemistry by ED-1 immunostaining (arrows) after 7, 14 or 21 days of treatment with vehicle (VH) or 15 mg/kg cyclosporine (CsA). The data are presented as the mean ± SD. * p<0.05 (CsA versus VH). Hematoxylin counterstain. Bars = 10 µm.
Late Injury (21 days)
Urinary Biomarkers.
After three weeks, urinary KIM-1 and TNF-α were still increased (respectively, 2.7 and 1.9 times) in the CsA group, but urinary fibronectin decreased to a value similar to that in the control group. Urinary osteopontin remained significantly increased in CsA-treated animals (2.4 times). At this time point, urinary TGF-β increased significantly (8.5 times) in the CsA-treated animals when compared with the control group (Figure 1).
Renal Tissue Histochemistry and Immunohistochemistry.
After three weeks, the renal expression of osteopontin (Figure 2 and Figure 3D), collagen IV (Figure 2 and Figure 4D), and tubulointerstitial α-SMA (Figure 2 and Figure 5H) remained significantly upregulated, and significantly more renal macrophages (Figure 6) were present in CsA-treated rats compared to control rats. At this time point, the renal expression of fibronectin was decreased and similar to that in the control group (Figure 2 and Figure 4H). After three weeks, the renal expression of vimentin (Figure 2 and Figure 5L) and TNF-α (Figure 2 and Figure 3H) was increased in CsA-treated animals compared with the control group. Renal tissue TGF-β was significantly overexpressed only after 21 days of CsA treatment (Figure 2 and Figure 4L).
None of the studied animals had detectable levels of podocin in their urine. There were no significant differences in the levels of urinary IL-6 or NGAL between CsA-treated and control group animals at any time point.
IL-6 renal expression was similar in CsA and control animals at all studied time points (Figure 2 and Figure 3, J–L).
Histopathological Assessment of Renal Damage
Tubulointerstitial fibrosis (Figure 5, A–D) was only observed in rats treated with CsA for 21 days (Figure 5, D). There was no detectable glomerular injury in CsA- or VH-treated animals at any time point.
Discussion
Salt-depleted rats were studied after one, two and three weeks of CsA or vehicle treatment, according to a well-established CsA nephrotoxicity model, to assess potential urinary biomarkers for the identification of different stages of CsA-induced kidney injury. The functional and structural changes found in CsA-treated animals in the present study are consistent with previously published results that utilized the same model of CsA nephrotoxicity.
The most interesting finding of this study is that increased levels of urinary KIM-1, TNF-α, fibronectin, osteopontin and TGF-β identified the different stages of CsA-induced nephrotoxicity, correlating consistently with tissue cytokine expression and the functional and structural kidney changes caused by CsA. If confirmed in clinical studies, these findings might allow the safer and more rational use of CsA in transplant and in autoimmune diseases patients.
Early injury (7 days)
KIM-1, TNF-α, microalbuminuria and fibronectin were significantly elevated urinary biomarkers in CsA-treated animals at the early time point, indicating acute nephrotoxicity. At this time point, the GFR was already impaired, but renal fibrosis was undetectable. After 7 days of CsA treatment, the renal expression of osteopontin, collagen IV and fibronectin was upregulated, suggesting that the mechanism that controls the later development of interstitial fibrosis was precociously activated in the course of CsA nephrotoxicity.
KIM-1 is an undetectable transmembrane glycoprotein in normal kidneys, which sheds into the urine after proximal tubular kidney injury. It has been consistently demonstrated as an early indicator of kidney injury in both rodents and humans [5], [7], [22] and is considered as a highly sensitive and specific urinary biomarker for monitoring drug-induced kidney injury [23]. KIM-1 was significantly increased at all stages of CsA-induced nephrotoxicity in the current study, suggesting that CsA-induced tubular injury occurs early, preceding interstitial fibrosis, and is a continuous process during the period of drug exposure.
TNF-α is a pleiotropic proinflammatory and immunoregulatory cytokine that acts as a mediator of tissue injury. In the kidney, infiltrating macrophages and endothelial, mesangial, glomerular, and tubular epithelial cells synthesize and release TNF-α. This cytokine is a key participant in the pathogenesis of kidney injury, triggering inflammation, apoptosis, and the accumulation of extracellular matrix, impairing glomerular blood flow and damaging the glomerular permeability barrier with the development of albuminuria [24]. Urinary TNF-α increased early after ischemia-reperfusion injury in pigs [25]. In the current study, the early increase in urinary TNF-α likely resulted from the direct action of CsA on resident renal cells or from tubular cells that suffered ischemia due to CsA-induced pre-glomerular vasoconstriction.
Fibronectin is a ubiquitous kidney matrix glycoprotein that connects epithelial cells via integrin to the extracellular matrix collagen [26]–[27]. Its overexpression occurs in experimental and clinical acute tubular injury [44]–[45] and in models of CsA-induced nephrotoxicity [28]–[29]. The early increase in the urinary excretion and renal tissue overexpression of fibronectin observed in this study were most likely associated with tubular injury resulting directly from CsA toxicity to renal tubular cells or CsA-induced renal ischemia.
Mid-term injury (14 days)
After 14 days of CsA treatment, the urinary excretion of KIM-1, TNF-α and fibronectin remained significantly elevated, and that of urinary osteopontin, increased significantly. At this midpoint, the renal tissue expression of osteopontin, collagen IV and fibronectin remained elevated, there was significant renal macrophage infiltration, and the kidney tubulointerstitial expression of α-SMA, a microfilament that marks epithelial-mesenchymal transition and fibroblast activation, increased significantly. These data indicated a transition from acute to chronic CsA-induced nephrotoxicity.
Osteopontin is a monocyte-macrophage adhesive protein produced primarily by the distal nephron [30]–[31] and secreted into urine [32] in the normal kidney. It attracts macrophages and participates in the development of renal fibrosis after kidney injury [14], [33]. Our results are consistent with previous data indicating that osteopontin contributes to chronic CsA-induced nephrotoxicity by recruiting macrophages, triggering epithelial-mesenchymal transition in renal tubular epithelial cells and promoting tubulointerstitial fibrosis [11], [34].
The elevated urinary KIM-1 at this point of the study was likely associated with fibrosis development. Renal interstitial fibrosis and chronic inflammation were already correlated with the elevated tissue expression and urinary release of KIM-1 [23], [35]. In a consistent way, treating salt-depleted rats with CsA for 18 days increased urinary KIM-1 excretion and promoted interstitial fibrosis (53). Urinary TNF-α levels remained elevated at the midpoint of the CsA treatment course in the current study. TNF-α is elevated during chronic inflammatory states, where it participates in the mechanisms controlling progressive renal damage by recruiting immune cells to the kidneys, and via direct effects on renal cells [36]. The increased urinary excretion and renal tissue expression of fibronectin observed at the midpoint of this study are consistent with the progression of chronic kidney injury. Increased urinary fibronectin correlates with the progression of renal dysfunction in primary glomerulopathies [37], and elevated renal expression of fibronectin was associated with interstitial fibrosis development [38].
Late injury (21 days)
Three weeks of CsA treatment caused overt CsA-induced chronic nephrotoxicity characterized by interstitial fibrosis. Urinary KIM-1 and osteopontin levels remained significantly elevated, urinary TNF-α peaked, most likely because of increased renal macrophage infiltration, and urinary TGF-β increased significantly for the first time in this study. Likewise, the renal expression of TGF-β increased significantly, the number of renal macrophages peaked, and accordingly, the renal expression of TNF-α significantly increased, indicating the progression of kidney chronic injury. CsA treatment for 21 days also significantly increased the renal expression of vimentin, a marker of proximal tubular cell injury and epithelial-mesenchymal transition. CsA-induced upregulation of vimentin expression in the renal tubule and interstitial area was previously observed in chronic CsA nephrotoxicity [39]–[42]. Consistently, the tubulointerstitial expression of α-SMA, collagen IV and osteopontin remained elevated, and the periglomerular expression of α-SMA increased significantly.
TGF-β, which is released by macrophages, is involved in the development of CsA-induced interstitial fibrosis [11], [43]–[47] and is related to the epithelial-mesenchymal transition process [29], [42], [48]–[51].
The combination of increased urinary KIM-1, osteopontin and TGF-β in this study indicated the development of chronic CsA nephrotoxicity.
Study Limitations
This was an animal model study, and thus, confirmation of these results by clinical studies is necessary before the possible use of these biomarkers in predicting CsA nephrotoxicity.
CsA-treated rats under low salt diet disclosed significantly lower BP values, particularly after 3 weeks of treatment. However, most of the observed changes in the urinary biomarkers (KIM-1, TNF-α, fibronectin, microalbuminuria) occurred after 7 days of treatment, when the intraarterial BP of CsA-treated rats was 81±4 mmHg. Only osteopontin and TGF-β, elevated when the BP decrease was more marked. Those biomarkers are associated to development of renal fibrosis, and it is improbable that their changes were due to the observed BP variation.
Conclusions
Urinary KIM-1, TNF-α, fibronectin, microalbuminuria, osteopontin and TGF-β were reliable biomarkers of CsA nephrotoxicity, correlating with the development of CsA-induced renal functional and structural injury and the temporal course of CsA nephrotoxicity from acute to chronic.
The clinical implications of these findings are evident. If proved efficacious in clinical studies, these biomarkers will allow the safer and more rational use of CsA.
Author Contributions
Conceived and designed the experiments: EAB SMO. Performed the experiments: CPC NMS. Analyzed the data: EAB SMO CPC NMS. Contributed reagents/materials/analysis tools: EAB SMO. Contributed to the writing of the manuscript: EAB SMO CPC.
References
- 1. Burdmann EA, Andoh TF, Yu L, Bennett WM (2003) Cyclosporine nephrotoxicity. Semin Nephrol 23: 465–476.
- 2. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM (1996) Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 50: 1089–1100.
- 3. Barrera-Chimal J, Bobadilla NA (2012) Are recently reported biomarkers helpful for early and accurate diagnosis of acute kidney injury? Biomarkers 17: 385–393.
- 4. Weekley CC, Peralta CA (2012) Advances in the use of multimarker panels for renal risk stratification. Curr Opin Nephrol Hypertens 21: 301–308.
- 5. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV (2006) Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 290: F517–F529.
- 6. Devarajan P (2008) NGAL in acute kidney injury: from serendipity to utility. Am J Kidney Dis 52: 395–399.
- 7. Vaidya VS, Ozer JS, Frank D, Collings FB, Ramirez V, et al. (2010) Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in multi-site preclinical biomarker qualification studies. Nat Biotechnol 28: 478–485.
- 8. Wasilewska A, Zoch-Zwierz W, Taranta-Janusz K, Michaluk-Skutnik J (2010) Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of cyclosporine nephrotoxicity? Pediatr Nephrol 25: 889–897.
- 9. Camici M (2007) Urinary detection of podocyte injury. Biomed Pharmacother 61: 245–249.
- 10. Petermann A, Floege J (2007) Podocyte damage resulting in podocyturia: a potential diagnostic marker to assess glomerular disease activity. Nephron Clin Pract 106: c61–c66.
- 11. Pichler RH, Franceschini N, Young BA, Hugo C, Andoh TF, et al. (1995) Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 6: 1186–1196.
- 12. Cai T, Mazzoli S, Meacci F, Tinacci G, Nesi G, et al. (2007) Interleukin-6. J Urol 178: 1906–1911.
- 13. Tesch GH (2008) MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 294: F697–F701.
- 14. Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, et al. (2009) Osteopontin modulates angiotensin II–induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 76: 32–43.
- 15. Upadhyay A, Larson MG, Guo CY, Vasan RS, Lipinska I, et al. (2011) Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant 26: 920–926.
- 16. Pruijm M, Ponte B, Vollenweider P, Mooser V, Paccaud F, et al. (2012) Not all inflammatory markers are linked to kidney function: results from a population-based study. Am J Nephrol 35: 288–294.
- 17. Cherney DZ, Scholey JW, Daneman D, Dunger DB, Dalton RN, et al. (2012) Urinary markers of renal inflammation in adolescents with Type 1 diabetes mellitus and normoalbuminuria. Diabet Med 29: 1297–1302.
- 18. Moresco RN, Sangoi MB, De Carvalho JA, Tatsch E, Bochi GV (2013) Diabetic nephropathy: traditional to proteomic markers. Clin Chim Acta 421: 17–30.
- 19. Haas M, Meehan SM, Josephson MA, Wit EJ, Woodle ES, et al. (1999) Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity. Am J Kidney Dis 34: 68–84.
- 20. Shihab FS, Yi H, Bennett WM, Andoh TF (2000) Effect of nitric oxide modulation on TGF-β1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 58: 1174–1185.
- 21. Ban CR, Twigg SM (2008) Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag 4: 575–596.
- 22. Vaidya VS, Ford GM, Waikar SS, Wang Y, Clement MB, et al. (2009) A rapid urine test for early detection of kidney injury. Kidney Int 76: 108–114.
- 23. Lim AI, Tang SC, Lai KN, Leung JC (2013) Kidney injury molecule-1: more than just an injury marker of tubular epithelial cells? J Cell Physiol 228: 917–924.
- 24. Sanchez-Niño MD, Benito-Martin A, Gonçalves S, Sanz AB, Ucero AC, et al. (2010) TNF superfamily: a growing saga of kidney injury modulators. Mediators Inflamm 2010
- 25. Hosgood SA, Hunter JP, Nicholson ML (2012) Early urinary biomarkers of warm and cold ischemic injury in an experimental kidney model. J Surg Res 174: e85–e90.
- 26. Singh P, Carraher C, Schwarzbauer JE (2010) Assembly of Fibronectin Extracellular Matrix. Annual Review of Cell and Developmental Biology 26: 397–419.
- 27. Ihara Y, Inai Y, Ikezaki M (2011) Alteration of integrin-dependent adhesion and signaling in EMT-like MDCK cells established through overexpression of calreticulin. J Cell Biochem 112: 2518–2528.
- 28. Esposito C, Grosjean F, Torreggiani M, Esposito V, Mangione F, et al. (2011) Sirolimus Prevents Short-Term Renal Changes Induced by Ischemia-Reperfusion Injury in Rats. Am J Nephrol 33: 239–249.
- 29. McMorrow T, Gaffney MM, Slattery C, Campbell E, Ryan MP (2005) Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. Nephrol Dial Transplant 20: 2215–2225.
- 30. Madsen KM, Zhang L, Abu Shamat AR, Siegfried S, Cha JH (1997) Ultrastructural localization of osteopontin in the kidney: Induction by lipopolysaccharide. J Am Soc Nephrol 8: 1043–1053.
- 31. Hudkins KL, Giachelli CM, Cui Y, Couser WG, Johnson RJ, et al. (1999) Osteopontin expression in fetal and mature human kidney. J Am Soc Nephrol 10: 444–457.
- 32. Min W, Shiraga H, Chalko C, Goldfarb S, Krishna GG, et al. (1998) Quantitative studies of human urinary excretion of uropontin. Kidney Int 53: 189–193.
- 33. Persy VP, Verhulst A, Ysebaert DK, De Greef KE, De Broe ME (2003) Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. Kidney Int 63: 543–553.
- 34. Xu D, Chen X, Deng Z, Tan R, Liu C, et al. (2014) Osteopontin mediating cyclosporine A induced epithelial-to-mesenchymal transition on rat renal tubular epithelial cells. Cell Biol Int 38: 8–15.
- 35. Waanders F, van Timmeren MM, Stegeman CA, Bakker SJ, van Goor H (2010) Kidney injury molecule-1 in renal disease. J Pathol 220: 7–16.
- 36. Ramseyer VD, Garvin JL (2013) Tumor necrosis factor-α regulation of renal function and blood pressure. Am J Physiol Renal Physiol 304: F1231–F1242.
- 37. Idasiak-Piechocka I, Oko A, Pawliczak E, Kaczmarek E, Czekalski S (2010) Elevated urinary fibronectin excretion predicts poor outcome in patients with primary chronic glomerulonephritis. Nephron Clin Pract 116: c47–c52.
- 38. Chen D, Chen Z, Park C, Centrella M, McCarthy T, et al. (2013) Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms. Gene 531: 23–30.
- 39. Sabry A, El-Husseini A, Sheashaa H, Abdel-Shafy E, El-Dahsahn K, et al. (2006) Colchicine vs. omega-3 fatty acids for prevention of chronic cyclosporine nephrotoxicity in Spraghe Dawley rats: an experimental animal model. Arch Med Res 37: 933–940.
- 40. Djamali A, Vidyasagar A, Adulla M, Hullett D, Reese S (2009) Nox-2 is a modulator of fibrogenesis in kidney allografts. Am J Transplant 9: 74–82.
- 41. Carlos CP, Mendes GEF, Miquelin AR, Luz MAM, Silva CGA, et al. (2010) Macrophage depletion attenuates chronic cyclosporine A nephrotoxicity. Transplantation 89: 1362–1370.
- 42. Young BA, Burdmann EA, Johnson RJ, Alpers CE, Giachelli CM, et al. (1995) Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 48: 439–448.
- 43. Disel U, Paydas S, Dogan A, Gulfiliz G, Yavuz S (2004) Effect of colchicine on cyclosporine nephrotoxicity, reduction of TGF-beta overexpression, apoptosis, and oxidative damage: an experimental animal study. Transplant Proc 36: 1372–1376.
- 44. Vieira JM Jr, Noronha IL, Malheiros DMAC, Burdmann EA (1999) Cyclosporine-induced interstitial fibrosis and arteriolar TGF-β expression with preserved renal blood flow. Transplantation 68: 1746–1753.
- 45. Di Paolo S, Grandaliano G, Gesualdo L, Ranieri E, Schena FP (1999) Low-density lipoproteins enhance transforming growth factor-beta 1 (TGF-β1) and monocyte chemotactic protein-1 (MCP-1) expression induced by cyclosporin in human mesangial cells. Clin Exp Immunol 117: 355–360.
- 46. Bobadilla NA, Gamba G (2007) New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol 293: F2–F9.
- 47. Lloberas N, Torras J, Alperovich G, Cruzado JM, Giménez-Bonafé P, et al. (2008) Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats. Nephrol Dial Transplant 23: 3111–3119.
- 48. Slattery C, Campbell E, McMorrow T, Ryan MP (2005) Cyclosporine A-induced renal fibrosis: a role for epithelial-mesenchymal transition. Am J Pathol 167: 395–407.
- 49. Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Inv 112: 1776–1784.
- 50. Liu Y (2004) Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15: 1–12.
- 51. Bottinger EP, Bitzer M (2002) TGF-β signaling in renal disease. J Am Soc Nephrol 13: 2600–2610.